Analog of prolactin-releasing peptide reduces body weight primarily through sustained fatty acid oxidation rather than hypophagia
Authors:
Open Access
- 1 December 2025
- journal article
- Published by Elsevier in Cell Metabolism
- Vol. 38 (1) , 100-114.e6
Abstract
No abstract availableKeywords
Funding Information
- Novo Nordisk
- Biotechnology and Biological Sciences Research Council (BB/W000989/1)
- Biotechnology and Biological Sciences Research Council (BB/P01867X/1)
This publication has 71 references indexed in Scilit:
- Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight LossJAMA, 2023
- A brainstem circuit for nausea suppressionCell Reports, 2022
- Describing the Weight‐Reduced State: Physiology, Behavior, and InterventionsObesity, 2021
- Thyroid Hormone Mimetics: the Past, Current Status and Future ChallengesCurrent Atherosclerosis Reports, 2016
- A Creatine-Driven Substrate Cycle Enhances Energy Expenditure and Thermogenesis in Beige FatCell, 2015
- GPR10 deficiency in mice results in altered energy expenditure and obesityBiochemical and Biophysical Research Communications, 2007
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Distribution and Characterization of Immunoreactive Prolactin-Releasing Peptide (PrRP) in Rat Tissue and PlasmaBiochemical and Biophysical Research Communications, 1999
- Neuropeptide FF reduces food intake in ratsPeptides, 1996
- Glucose kinetics during acute and chronic treatment of rats with 2[6(4-chloro-phenoxy) hexyl]oxirane-2-carboxylate, etomoxirBiochemical Pharmacology, 1987